Equilibrium studies of zinc(II) and cobalt(II) binding to tripeptide analogues of the amino terminus of human serum albumin

Serum albumin is known to bind several divalent metal ions at the amino terminus of the protein. Two peptide analogues for the amino terminus of human albumin, L-aspartyl-L-alanyl-L-histidine-N-Methyl amide (AAHNMA) and glycylglycyl-L-histidine-N-methyl amide (GGHNMA) have been synthesized, and their interactions with Zn(II) and Co(II) ions have been studied using analytical potentiometry. The stability constants of the species and their distribution as a function of pH were determined in 0.16-M KNO₃ at 25°. Comparison of the modes of interaction of the Zn(II) and Co(II) with each of the above peptides indicate that, although Co(II) is a valuable tool for the study of Zn(II) interaction with metalloenzymes, it is considerably less useful as a Zn(II) model with small peptide molecules. The potentiometric properties of the two peptide-Zn(II) systems have been compared to the potentiostatic properties of the albumin-Zn(II) system. The results indicate that AAHNMA is a better analogue for the Zn(II)-HSA interaction than is GGHNMA. The findings suggest that the Zn(II)-HSA binding site is best described as a compound site containing both a histidyl and a neighboring carboxyl group.     

Antiangiogenic effects of GFP08, an agaran-type polysaccharide isolated from Grateloupia filicina

An agaran-type polysaccharide, GFP08, isolated from Grateloupia filicina (C. Agardh) Lamouroux, was mainly composed of 1,3-linked β-d-galactose partially sulfated at position O-2 and 1,4-linked α-l-galactose O-2, O-3-disulfate, α-l-galactose O-6-sulfate and 3,6-anhydro-α-l-galactose. Small quantities of xylose, 4,6-O-(1'-carboxyethylidene) and 6-O-methyl-β-d-galactose were also present. In mice bearing sarcoma-180 cells, GFP08 decreased tumor weight in a dose-dependent manner. The antiangiogenic activity of GFP08 was evaluated using the chicken chorioallantoic membrane assay, and the results showed that GFP08 dose-dependently reduced new vessel formation. Meanwhile, GFP08 inhibited the differentiation of human umbilical vein endothelial cells (HUVECs) into capillary-like structures in vitro and reduced the number of migrated cells. However, there was no observed cytotoxicity of GFP08 toward HUVECs. Further study revealed that GFP08 decreased tissue factor (TF) expression without affecting the activities of matrix metalloproteinase-2 and -9. All those data indicated that GFP08 had an antitumor effect that might be associated in part with its antiangiogenic effect through down-regulating the expression of TF protein.     

Mammalian CAP interacts with CAP,CAP2, and actin

We previously identified human CAP, a homolog of the yeast adenylyl cyclase—associated protein. Previous studies suggest that the N-terminal and C-terminal domains of CAP have distinct functions. We have explored the interactions of human CAP with various proteins. First, by performing yeast two-hybrid screens, we have identified peptides from several proteins that interact with the C-terminal and/or the N-terminal domains of human CAP. These peptides include regions derived from CAP and BAT3, a protein with unknown function. We have further shown that MBP fusions with these peptides can associate in vitro with the N-terminal or C-terminal domains of CAP fused to GST. Our observations indicate that CAP contains regions in both the N-terminal and C-terminal domains that are capable of interacting with each other or with themselves. Furthermore, we found that myc-epitope-tagged CAP coimmunoprecipitates with HA-epitope-tagged CAP from either yeast or mammalian cell extracts. Similar results demonstrate that human CAP can also interact with human CAP2. We also show that human CAP interacts with actin, both by the yeast two-hybrid test and by coimmunoprecipitation of epitope-tagged CAP from yeast or mammalian cell extracts. This interaction requires the C-terminal domain of CAP, but not the N-terminal domain. Thus CAP appears to be capable of interacting in vivo with other CAP molecules, CAP2, and actin. We also show that actin co-immunoprecipitates with HA-CAP2 from mammalian cell extracts. © 1996 Wiley-Liss, Inc.